Etienna Bio, Inc. Announces Formation of Scientific Advisory Board with Renowned UMass Chan Leaders
Etienna Bio Secures Exclusive Worldwide License from UMass Chan Medical School for Novel Adipose-Derived Regenerative Platform LEAWOOD, Kan., Feb. 11, 2026 — Etienna Bio, Inc., a regenerative biotechnology company developing an autologous adipose-derived cell platform for aesthetic and reconstructive applications, today…
